他莫昔芬延缓小鼠肌萎缩侧索硬化(Als)模型的疾病进展
WESTPORT, CT (Reuters Health) - Tamoxifen treatment causes a significant delay of symptoms and disease progression in mice infected with an amyotrophic lateral sclerosis-like syndrome, according to Dr. Benjamin R. Brooks and colleagues at the University of Wisconsin in Madison.
The team analyzed the efficacy of tamoxifen treatment in a mouse model of ALS after observing that a female patient of Dr. Brooks had slower progression of ALS while receiving tamoxifen for breast cancer. Dr. Brooks presented the findings Monday during the Society of Neuroscience meeting in San Diego.
In mice treated with either placebo or tamoxifen (0.2, 0.5 or 1.0 mg/kg per day), "peak effect [was seen] at the 0.5-mg dose, causing a significant delay of symptoms," Dr. Brooks told Reuters Health. He added that all three doses of tamoxifen were more effective than placebo.
The median time to onset of paralysis in the untreated mice was 36 days compared with 58 days in the treated groups, Dr. Brooks said. He added that time to disease progression without treatment was 8 days compared with 17 days in the 0.5-mg group. There was no difference between treated male and female mice in delay of disease onset or progression.
These findings indicate that "tamoxifen not only delays disease progression, but may be an effective treatment" for ALS in humans, Dr. Brooks said. He added that a clinical trial is under way to determine the efficacy of tamoxifen treatment in ALS patients.
Dr. Brooks noted that tamoxifen has protein kinase-C inhibitory activity similar to that of riluzole, a current treatment for ALS. He believes that study of this inhibitory activity may be "an area of investigation into a whole new pathway of the cause of ALS.", http://www.100md.com
The team analyzed the efficacy of tamoxifen treatment in a mouse model of ALS after observing that a female patient of Dr. Brooks had slower progression of ALS while receiving tamoxifen for breast cancer. Dr. Brooks presented the findings Monday during the Society of Neuroscience meeting in San Diego.
In mice treated with either placebo or tamoxifen (0.2, 0.5 or 1.0 mg/kg per day), "peak effect [was seen] at the 0.5-mg dose, causing a significant delay of symptoms," Dr. Brooks told Reuters Health. He added that all three doses of tamoxifen were more effective than placebo.
The median time to onset of paralysis in the untreated mice was 36 days compared with 58 days in the treated groups, Dr. Brooks said. He added that time to disease progression without treatment was 8 days compared with 17 days in the 0.5-mg group. There was no difference between treated male and female mice in delay of disease onset or progression.
These findings indicate that "tamoxifen not only delays disease progression, but may be an effective treatment" for ALS in humans, Dr. Brooks said. He added that a clinical trial is under way to determine the efficacy of tamoxifen treatment in ALS patients.
Dr. Brooks noted that tamoxifen has protein kinase-C inhibitory activity similar to that of riluzole, a current treatment for ALS. He believes that study of this inhibitory activity may be "an area of investigation into a whole new pathway of the cause of ALS.", http://www.100md.com